Journal article

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

MJ Maurer, TM Habermann, Q Shi, N Schmitz, D Cunningham, M Pfreundschuh, JF Seymour, U Jaeger, C Haioun, H Tilly, H Ghesquieres, F Merli, M Ziepert, R Herbrecht, J Flament, T Fu, CR Flowers, B Coiffier

Annals of Oncology | OXFORD UNIV PRESS | Published : 2018

Grants

Awarded by National Institutes of Health University of Iowa/Mayo Clinic Lymphoma SPORE


Funding Acknowledgements

This work was supported by grants from Celgene Corporation. Data were transmitted directly from original study cooperative groups to the Mayo Clinic. Celgene Corporation supported organization and meetings of the SEAL group. The National Institutes of Health University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274) grant provided support for MJM and TMH.